CTI Molecular Imaging Announces the Release of PET.CONNECT(TM)

CTI Molecular Imaging Announces the Release of PET.CONNECT(TM)
CTI Expands its Product Line 


KNOXVILLE, Tenn., Nov. 29  /PRNewswire-FirstCall/ -- CTI Molecular Imaging,
Inc. (NASDAQ:CTMI), a leading provider of positron emission tomography (PET)
equipment, molecular biomarkers and services, today announced that its
subsidiary CTI PETNET will release and distribute PET.CONNECT, an innovative
application that includes a wide range of IT products, educational programs and
service offerings, designed to provide all the capabilities necessary to run a
successful PET imaging practice.

PET.CONNECT consists of innovative applications for Image Analysis, PET
Education and Marketing, and Practice Management. The Image Analysis software
in PET.CONNECT, created by CTI Mirada Solutions, includes a suite of diagnostic
applications spanning oncology, neurology, and cardiology. The PET Education
and Marketing programs are designed to provide the user with all the tools
necessary to educate their community on the advantages of PET and PET/CT. The
integrated Practice Management applications provide a turnkey solution to
streamlining the daily operations of a PET center.  By combining reliable dose
delivery, image analysis software, PET education and marketing with practice
management tools, CTI PETNET offers PET providers the most powerful range of
services available to increase productivity, improve diagnostic accuracy and
successfully grow their practice.

"Building a successful PET practice requires highly specialized resources and
expertise not found with other modalities. With the creation of PET.CONNECT, we
have made it easier for our customers to succeed by integrating these
requirements into one cohesive program," said Joe Sardano, Senior Vice
President of Sales and Marketing.

"In addition to CTI Mirada products like the MiraView(TM) workstation for image
review and analysis, and Fusion7D(TM) with rigid and non-rigid image fusion
capabilities, PET.CONNECT includes exciting new products like Novisis(TM), an
invaluable tool in monitoring response to therapy or disease progression over
time," said Christian P. Behrenbruch, President of CTI Mirada Solutions.

Through the creation of PET.CONNECT, CTI Molecular Imaging and its subsidiaries
are providing the tools and services necessary to make a PET imaging practice
successful.

About CTI Molecular Imaging:

CTI Molecular Imaging, Inc. is a leading supplier of products and services for
positron emission tomography (PET), a diagnostic imaging technology used in the
detection and treatment of cancer, neurological disorders, and cardiac disease.
Additional information is available at: http://www.ctimi.com/ . Certain matters
discussed in this press release constitute forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements, which may be identified by words such as "assume,"
"expect," "anticipate," "intend," "estimate" or similar expressions, include
statements regarding the anticipated financial impact and operational
improvements resulting from the new distribution arrangement with Siemens and
any other statements that necessarily depend on future events. Forward-looking
statements involve a number of risks and uncertainties and there can be no
assurance that any forward-looking statements will prove to be accurate.
Various factors could cause actual results to differ materially from those
anticipated in the forward-looking statements. CTI undertakes no obligation to
update or revise any forward-looking statements. Further information regarding
risks, uncertainties and other factors that could adversely affect CTI or cause
actual results to differ materially from those anticipated in forward-looking
statements are included in CTI's Annual Report on Form 10-K for the fiscal year
ended September 30, 2003 and Quarterly Report on Form 10-Q for the quarter
ended June 30, 2004. 

Website:  http://www.ctimi.com 

DATASOURCE: CTI Molecular Imaging, Inc.



CONTACT:  Lisa Baird of CTI Molecular Imaging, Inc., [phone]

Copyright